Leading brokerage firms have recently initiated fresh coverage on a selection of Indian companies, identifying them as top stock ideas with substantial growth potential. These analyses, released on July 16, 2026, highlight several firms, including Saatvik Green Energy, Privi Speciality Chemicals Ltd, Kusumgar, Rainbow Childrens Medicare Ltd, and Filatex India Ltd, with some projections indicating an upside of up to 113%.
Firms like Motilal Oswal Financial Services, InCred Equities, Emkay Global Financial Services, IDBI Capital, and Sunidhi Institutional Equities have issued positive ratings, citing various factors from market leadership to strategic expansions.
Saatvik Green Energy: Expanding Solar Horizons
Motilal Oswal Financial Services has initiated coverage on Saatvik Green Energy Ltd (SGEL) with a 'Buy' rating and a target price of Rs 565, suggesting a 20% upside. By the end of FY26, SGEL boasts an installed module manufacturing capacity of 4.8GW, with plans to expand by an additional 4GW and venture into cell manufacturing with a planned 6GW capacity. Motilal Oswal forecasts SGEL's module/cell manufacturing capacities to reach 8.8GW/2.4GW by FY27 and 8.8GW/6GW by FY28. The company also intends to enter the ingot-wafer segment by FY29, strengthening its backward integration.
Privi Speciality Chemicals: Margin Growth Ahead
InCred Equities recommends an 'Add' rating for Privi Speciality Chemicals, setting a target price of Rs 4,796, indicating a 30% upside. Analysts anticipate gross margins to remain around 48% and EBITDA margins between 25-26%, driven by higher utilization, an improved product mix, and operational leverage. Capacity ramp-up and better realization are expected to boost EPS to approximately Rs 123 in FY28F and Rs 151 in FY29F. The firm highlights sticky customer relationships, visible capacity growth, and backward integration as key supportive factors, though raw material cost inflation remains a potential risk.
Kusumgar: Engineered Fabrics Specialist
Emkay Global Financial Services has given Kusumgar a 'Buy' rating with a target price of Rs 800, implying a 33% upside. Kusumgar specializes in engineered fabrics, including high-performance woven, coated, and laminated synthetics for aerospace, defense, industrial, and outdoor markets. The company, known for manufacturing military parachute fabric, has over 1,000 difficult-to-replicate fabric SKUs. Emkay Global projects revenue/EBITDA/PAT CAGR of 34%/35%/46% respectively over FY26-29E, citing growth in its defense segment and diversification efforts.
Rainbow Children's Medicare: Pediatric Healthcare Leader
IDBI Capital has initiated coverage on Rainbow Children's Medicare with a 'Buy' rating and a target price of Rs 1,744, suggesting a 16% upside. As India's largest multi-specialty pediatric and perinatal hospital chain, Rainbow operates 24 hospitals and 5 outpatient clinics. The brokerage firm notes its strong position to capitalize on the underpenetrated pediatric and maternal healthcare market in India, supported by its leadership in pediatric critical care, integrated care platform, and asset-light expansion strategy. IDBI Capital estimates revenue/EBITDA/PAT CAGRs of 18.0%/18.5%/18.2% over FY26-FY28E.
Filatex India: Polyester Yarn Innovator
Sunidhi Institutional Equities has rated Filatex India Ltd as a 'Buy' with an ambitious target price of Rs 150, indicating a significant 113% upside. The brokerage firm projects a 11%/32%/40% CAGR for revenue/EBITDA/PAT respectively from FY26-28E. Filatex India's business is valued using a sum-of-the-parts approach, with its virgin fiber legacy business valued at 9 times EBITDA and its ECOSIS business at 25 times EBITDA, anticipating substantial tailwinds. Sunidhi highlights Filatex's capital-efficient operations and prudent capital allocation strategies as key strengths.